Dr. Jason S. Xiang: Founder and Chief Executive Officer

Xiang.png

Dr. Xiang is an accomplished Medicinal Chemist with over 20 years’ experience in discovery and development of therapeutics for oncology, autoimmune and metabolic diseases. Dr. Xiang’s expertise spans multiple therapeutic modalities including small molecules, antibody-drug conjugates, bifunctional protein degraders (PROTACs), etc. Dr. Xiang led numerous preclinical and development programs that led to multiple clinical products including three commercial products. Prior to founding Polymed, Dr. Xiang led the research and development team at Suzhou Kintor (HKG:9939) as Chief Technology Officer, and led Chemistry Department at Shanghai ChemPartner as Vice President for 6 years. Dr. Xiang started his industrial career at Wyeth Pharmaceuticals (acquired by Pfizer Inc.)/Pfizer Inc., where he led preclinical drug discovery teams during his 13 yr career. Dr. Xiang has received numerous awards such as Monsanto Outstanding Research Award, Abbott Excellent Organic Research Award, Wyeth Clinical Candidate Award and 2017 Shanghai Small Business Innovation Award. He published 63 research articles in top-tier journals and 18 Issued patents. In addition to his scientific acumen, Dr. Xiang is a proven goal-oriented business leader and has developed business strategy, raised funds for early-stage ventures and executed on strategic collaborations with large pharma, biotech, venture and academic partners.


Dr. He Zhou, SVP,Pharmacology, Regulatory Affairs and Clinical Operation

Zhou.png

Dr, Zhou is a seasoned industry veteran with 20+ years of experience in preclinical/clinical drug development, and management. Prior to joining Polymed, Dr. Zhou served as Head of Oncology Pharmacology at Momenta Pharmaceuticals (a wholly-owned subsidiary of Johnson & Johnson), Head of Oncology Pharmacology and Executive Director at Shanghai ChemPartner, Senior Director in Clinical Biomarker at BeiGene, China General Manager and VP at HiFiBiO Therapeutics, Head of Research and VP at Beijing Migrasome Therapeutics. She led multiple projects, including 5 (3 antibodies, a small molecule, and a carbohydrate) as a core member through screening to successful IND filing, with 10+ drug candidates entering clinical trials, 3 approved and marketed. With her medical training, she also participated in multiple Phase I-III clinical trials in US and China, led and completed 1 Phase I clinical trial in China.

Dr. Zhou received her B.S. in Medicine and a M.S. in Immunology from Peking University Health Science Center (formerly Beijing Medical University) and her Ph.D. in Immunology from University of Mississippi Medical Center. She completed her postdoctoral training in Immuno-Oncology in Dr. Ralph Reisfeld’s laboratory at The Scripps Research Institute. She has published 40 research articles in high-impact journals such as Cancer Cell and Nature Communications, and 6 issued patents.


Dr.Yong Guo,SVP,CMO,Clinical Development

人1.png

With a background as a clinical surgeon, Dr Guo has over 20 years of clinical research and development experience in both China and the United States, along with extensive expertise in tumor molecular immunology and preclinical drug discovery. He has been deeply involved in more than 20 phase I-III clinical trials in both China and the U.S., covering the entire lifecycle of new drug development and management, ensuring timely and accurate decision-making and responses at each clinical stage. He has successfully initiated and led multiple multi-center clinical trials covering solid tumors, hematologic tumors, and non-tumor indications. Among his major accomplishments, he led the first PD-1 combination therapy clinical trial in China (presented at ASCO 2019) and the Phase III clinical trial of Flumatinib for chronic myeloid leukemia, which was approved by the NMPA for marketing in 2019. He has held various senior positions at well-known pharmaceutical companies in both China and the U.S., including Sanofi (U.S.), Mitsubishi Tanabe Pharmaceutical (U.S.), Jiangsu Hengrui, Hansoh Pharmaceuticals, and several other biotech companies, serving as Medical Director, Senior Vice President (SVP), CEO, and Chief Medical Officer (CMO). He holds an MD degree from Nanjing Medical University, completed a 3-year postgraduate clinical training in general surgery at Jiangsu Provincial People's Hospital, and a 4-year postdoctoral fellowship in tumor molecular immunology at New York University School of Medicine.

 

 Dr. Yufeng Chen, SVP, Medchem

Chen.png

Dr. Chen brings in more than 20 years of small-molecule drug discovery experiences. Prior to joining Polymed, Dr. Chen worked at Shanghai ChemPartner and Hangzhou Adelai Nortye Biopharma with increasing responsibilities. He successfully advanced three projects into clinical stages. Dr. Chen received his Ph.D. in Organic Chemistry from Shanghai Institute of Materia Medica, Chinese Academy of Sciences. He received his postdoctoral training at Georgetown University and  University of Illinois at Chicago. 


Dr. Bing Zhang, VP, BD and Operations 

Zhang.png

Dr. Zhang has ten years of experiences in novel drug discovery. Prior to Polymed, Dr. Zhang worked as an Associate Director at Viva Biotech,and a Director at ChiaTai Tianqing Pharmaceutical Group. Dr. Zhang received his Ph.D. in Biology at Durham University, UK and completed his Postdoctoral training at Oklahoma State University, USA.